MRNA vs ONC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ONC Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BeOne Medicines Ltd. American Depositary Shares (ONC) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus ONC at 36.2x Forward P/E and 17.8% operating margin (+33.8% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against ONC sits in UNCLASSIFIED (23rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | ONC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $45.7B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 51.2x | Lower Multiple | MRNA |
| Forward P/E Ratio Valuation | 23.0x | 36.2x | Lower Multiple | MRNA |
| Revenue Growth (YoY) Growth | +29.2% | +33.8% | Higher Growth | ONC |
| Operating Margin (TTM) Profitability | -80.8% | 17.8% | Higher Margin | ONC |
| Net Profit Margin Profitability | -110.5% | 13.9% | Higher Margin | ONC |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 18.4% | Higher ROE | ONC |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 80% ($254โ$425) | Stronger Trend | ONC |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.67ฮฒ ยท 37% Vol | Lower Realized Risk | ONC |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 48.0 / 100 (HOLD) | Higher Composite | ONC |